Abstract
Hyperphosphatemic familial tumoral calcinosis (HFTC) is an autosomal recessive metabolic disorder characterized by extensive phenotypic and genetic heterogeneity. HFTC was shown recently to result from mutations in two genes: GALNT3, coding for a glycosyltransferase responsible for initiating O-glycosylation, and FGF23, coding for a potent phosphaturic protein. All GALNT3 mutations reported so far have been identified in patients of either Middle Eastern or African-American extraction, corroborating numerous historical reports of the disorder in Africa and in the Middle East. In the present study, we describe a patient of Northern European origin displaying typical features of HFTC. Mutation analysis revealed that this patient carries a homozygous novel nonsense mutation in GALNT3 predicted to result in the synthesis of a significantly truncated protein. The present results expand the spectrum of known mutations in GALNT3 and demonstrate the existence of HFTC-causing mutations in this gene outside the Middle Eastern and African-American populations.
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Araya K, Fukumoto S, Backenroth R, Takeuchi Y, Nakayama K, Ito N, Yoshii N, Yamazaki Y, Yamashita T, Silver J, Igarashi T, Fujita T (2005) A novel mutation in fibroblast growth factor 23 gene as a cause of tumoral calcinosis. J Clin Endocrinol Metab 90:5523–5527
Benet-Pagès A, Orlik P, Strom TM, Lorenz-Depiereux B (2005) An FGF-23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia. Hum Mol Genet 14:385–390
Berndt TJ, Schiavi S, Kumar R (2005) Phosphatonins and the regulation of phosphorus homeostasis. Am J Physiol Renal Physiol 289:F1170–1182
Burkes EJ Jr, Lyles KW, Dolan EA, Giammara B, Hanker J (1991) Dental lesions in tumoral calcinosis. J Oral Pathol Med 20:222–227
Chefetz I, Heller R, Galli-Tsinopoulou A, Richard G, Wollnik B, Indelman M, Koerber F, Topaz O, Bergman R, Sprecher E, Schoenau E (2005) A novel homozygous missense mutation in FGF23 causes familial tumoral calcinosis associated with disseminated visceral calcification. Hum Genet 118:261–266
Frishberg Y, Topaz O, Bergman R, Behar D, Fisher D, Gordon D, Richard G, Sprecher E (2005) Identification of a recurrent mutation in GALNT3 demonstrates that hyperostosis-hyperphosphatemia syndrome and familial tumoral calcinosis are allelic disorders. J Mol Med 83:33–38
Fukumoto S (2005) Post-translational modification of fibroblast growth factor 23. Ther Apher Dial 9:319–322
Gal G, Metzker A, Garlick J, Gold Y, Calderon S (1994) Head and neck manifestations of tumoral calcinosis. Oral Surg Oral Med Oral Pathol 77:158–166
Hawass N el-D, Kolawole T, Ismail AH, Patel PJ (1988) Tumoral calcinosis: case reports from Saudi Arabia with a review of the literature. Trop Geogr Med 40:58–63
Ichikawa S, Lyles KW, Econs MJ (2005) A novel GALNT3 mutation in a pseudo-autosomal dominant form of tumoral calcinosis: evidence that the disorder is autosomal recessive. J Clin Endocrinol Metab 90:2420–2423
Inoue Y, Segawa H, Kaneko I, Yamanaka S, Kusano K, Kawakami E, Furutani J, Ito M, Kuwahata M, Saito H, Fukushima N, Kato S, Kanayama HO, Miyamoto K (2005) Role of the vitamin D receptor in FGF23 action on phosphate metabolism. Biochem J 390:325–331
Jain SP (1989) Tumoral calcinosis in Somalia and Ethiopia: a report of twenty one cases and brief review of literature. East Afr Med J 66:476–480
Larsson T, Yu X, Davis SI, Draman MS, Mooney SD, Cullen MJ, White KE (2005) A novel recessive mutation in Fibroblast growth factor-23 (FGF23) causes familial tumoral calcinosis. J Clin Endocrinol Metab 90:2424–2427
McClatchie S, Bremner AD (1969) Tumoural calcinosis—an unrecognized disease. Br Med J 1:153–155
Metzker A, Eisenstein B, Oren J, Samuel R (1988) Tumoral calcinosis revisited—common and uncommon features. Report of ten cases and review. Eur J Pediatr 147:128–132
Miyamoto K, Ito M, Kuwahata M, Kato S, Segawa H (2005) Inhibition of intestinal sodium-dependent inorganic phosphate transport by fibroblast growth factor 23. Ther Apher Dial 9:331–335
Saito H, Kusano K, Kinosaki M, Ito H, Hirata M, Segawa H, Miyamoto K, Fukushima N (2003) Human fibroblast growth factor-23 mutants suppress Na+-dependent phosphate co-transport activity and 1alpha,25-dihydroxyvitamin D3 production. J Biol Chem 278:2206–2211
Shimada T, Yamazaki Y, Takahashi M, Hasegawa H, Urakawa I, Oshima T, Ono K, Kakitani M, Tomizuka K, Fujita T, Fukumoto S, Yamashita T (2005) Vitamin D receptor-independent FGF23 actions in regulating phosphate and vitamin D metabolism. Am J Physiol Renal Physiol 289:F1088–F1095
Smack D, Norton SA, Fitzpatrick JE (1996) Proposal for a pathogenesis-based classification of tumoral calcinosis. Int J Dermatol 35:265–271
Ten Hagen KG, Fritz TA, Tabak LA (2003) All in the family: the UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferases. Glycobiology 13:1R–16R
Topaz O, Shurman D, Bergman R, Indelman M, Ratajczak P, Mizrachi M, Khamaysi Z, Behar D, Petronius D, Friedman V, Zelikovic I, Raimer S, Metzker A, Richard G, Sprecher E (2004) Mutations in GALNT3, encoding a protein involved in O-linked glycosylation, cause familial tumoral calcinosis. Nat Genet 36:579–581
Vogt G, Chapgier A, Yang K, Chuzhanova N, Feinberg J, Fieschi C, Boisson-Dupuis S, Alcais A, Filipe-Santos O, Bustamante J, de Beaucoudrey L, Al-Mohsen I, Al-Hajjar S, Al-Ghonaium A, Adimi P, Mirsaeidi M, Khalilzadeh S, Rosenzweig S, de la Calle Martin O, Bauer TR, Puck JM, Ochs HD, Furthner D, Engelhorn C, Belohradsky B, Mansouri D, Holland SM, Schreiber RD, Abel L, Cooper DN, Soudais C, Casanova JL (2005) Gains of glycosylation comprise an unexpectedly large group of pathogenic mutations. Nat Genet 37:692–700
Yu X, Ibrahimi OA, Goetz R, Zhang F, Davis SI, Garringer HJ, Linhardt RJ, Ornitz DM, Mohammadi M, White KE (2005) Analysis of the biochemical mechanisms for the endocrine actions of fibroblast growth factor-23. Endocrinology 146:4647–4656
Acknowledgements
We acknowledge the family for having participated in the present study. We are grateful to V. Friedman for DNA sequencing services. This study was supported in part by grants provided by the Israel Science Foundation and the Rappaport Family Institute for Research in the Medical Sciences.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Specktor, P., Cooper, J.G., Indelman, M. et al. Hyperphosphatemic familial tumoral calcinosis caused by a mutation in GALNT3 in a European kindred. J Hum Genet 51, 487–490 (2006). https://doi.org/10.1007/s10038-006-0377-6
Received:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1007/s10038-006-0377-6
Keywords
This article is cited by
-
Hyperphosphatemic familial tumoral calcinosis caused by a novel variant in the GALNT3 gene
Journal of Endocrinological Investigation (2020)
-
Hyperphosphatemic familial tumoral calcinosis secondary to fibroblast growth factor 23 (FGF23) mutation: a report of two affected families and review of the literature
Osteoporosis International (2018)
-
Human Preosteoblastic Cell Culture from a Patient with Severe Tumoral Calcinosis-Hyperphosphatemia Due to a New GALNT3 Gene Mutation: Study of In Vitro Mineralization
Calcified Tissue International (2015)
-
Long-term clinical outcome and phenotypic variability in hyperphosphatemic familial tumoral calcinosis and hyperphosphatemic hyperostosis syndrome caused by a novel GALNT3mutation; case report and review of the literature
BMC Genetics (2014)
-
Familial tumoral calcinosis in two Chinese patients: a case series
Journal of Medical Case Reports (2011)
